What to know
- Presentation Day/Time: Thursday, April 24, 9:00–10:25 am
- Presenter: Shawn Thomas, PhD, MPH, EIS officer assigned to the National Center on Birth Defects and Developmental Disabilities, Division of Birth Defects and Infant Disorders
What did we do?
- We calculated the prevalence of neonatal abstinence syndrome (NAS) and neonatal opioid withdrawal syndrome (NOWS) among infants born to women with an opioid use disorder (OUD) using different public health and clinical case definitions, examining how these definitions overlap to help inform identification practices.
What did we find?
- NAS prevalence among infants born to persons with OUD ranged from 47% to 75%.
- Among infants meeting CSTE's 2023 NAS Tier 1 standardized surveillance case definition, 72% had an ICD-9/10-CM code for NAS.
- Among infants meeting the NOWS clinical case definition, 62% had an ICD-9/10-CM code for NAS.
Why does it matter?
- NAS prevalence varied by case definitions.
- ICD-9/10-CM codes alone might underestimate NAS prevalence.
- Leveraging additional information to identify NAS beyond ICD codes can improve surveillance and estimate prevalence, which might help ensure that affected families can be identified and referred to support services.
***This presentation has updated data that will be shared at the EIS Conference.
Abstract Category: Maternal, Child, and Adolescent Health